Takeda (TAK) announced the FDA has approved HYQVIA for the treatment of chronic inflammatory demyelinating polyneuropathy as maintenance therapy to prevent the
relapse of neuromuscular disability and impairment in adults. HYQVIA is now available as a maintenance therapy for adult patients with chronic inflammatory demyelinating polyneuropathy in the U.S.
"With the FDA approval of HYQVIA for CIDP, we can now offer a personalized maintenance treatment option for adults with this debilitating disease," said Giles Platford, president of Takeda's Plasma-Derived Therapies Business Unit.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com